2-甲基-5-苯基-3-糠醛 | 321309-42-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-甲基-5-苯基-3-糠醛
• 英文名称: 2-methyl-5-phenylfuran-3-carbaldehyde
• 英文别名: 2-methyl-5-phenyl-3-furaldehyde
• CAS: 321309-42-6
• 化学式: C₁₂H₁₀O₂
• mdl: MFCD02681964
• 分子量: 186.21
• InChiKey: QRBXYIYZWZGINC-UHFFFAOYSA-N

物化性质

• 熔点：
  49 °C
• 沸点：
  302.6±30.0 °C(Predicted)
• 密度：
  1.125±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.083
• 拓扑面积：
  30.2
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2932190090

SDS

Name:	2-Methyl-5-phenyl-3-furaldehyde 97% Material Safety Data Sheet
Synonym:
CAS:	321309-42-6

Section 1 - Chemical Product MSDS Name:2-Methyl-5-phenyl-3-furaldehyde 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
321309-42-6	2-Methyl-5-phenyl-3-furaldehyde	97%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Moisture sensitive.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 321309-42-6: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: pale yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 49 - 51 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C12H10O2
Molecular Weight: 186

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials, exposure to moist air or water.
Incompatibilities with Other Materials:
Strong oxidizing agents, reducing agents.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide, acrid smoke and fumes.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 321309-42-6 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2-Methyl-5-phenyl-3-furaldehyde - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 321309-42-6: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 321309-42-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 321309-42-6 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-甲基-5-苯基-3-糠醛 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 乙腈 为溶剂， 以74.3%的产率得到4-bromo-2-methyl-5-phenylfuran-3-carbaldehyde
  参考文献：
  名称：

  SUBSTITUTED FURANS AND THEIR USE

  摘要：

  本申请涉及新颖的取代呋喃衍生物，涉及它们的制备方法，涉及它们用于治疗和/或预防疾病以及用于制备治疗和/或预防疾病药物的用途，特别是用于治疗和/或预防心血管疾病。

  公开号：

  US20110054017A1
• 作为产物：
  描述：

  戴斯-马丁氧化剂 在 乙酸乙酯 、 碳酸氢钠 、 magnesium sulfate 、 silica gel 、 ethyl acetate n-hexane 作用下， 以 水 为溶剂， 反应 2.0h， 以to give the title compound (3.6 g, 78%) as a yellow crystal的产率得到2-甲基-5-苯基-3-糠醛
  参考文献：
  名称：

  HETEROCYCLIC COMPOUND

  摘要：

  本发明提供了一种由以下式（I）表示的杂环化合物，该化合物具有葡萄糖高升素拮抗作用，并可用于预防或治疗糖尿病等疾病，其中，式中环A为可选取代苯环等；Y为氮原子等；X为—O—等；R4为氢原子等；R5和R6各自独立地为氢原子等；R1为可选取代的碳氢基团等；R2为氢原子等；R3为—（CH2）3—COOH等，或其盐。

  公开号：

  US20100256156A1

文献信息

• Synthesis of 3-Formylfurans <i>via</i> a Silver(I)-Catalyzed Epoxide Ring-Opening/1,2-Acyl Migration/Cyclization Cascade
  作者：Jing Wang、Chen Shen、Tao Wang、Sheng Mo、Xingxin Li、Zunting Zhang

  DOI：10.1002/adsc.201600938

  日期：2016.12.22

  By the design of suitable starting materials, a silver(I)‐catalyzed epoxide ring‐opening/1,2‐acyl migration/cyclization cascade has been developed, which allowed us to systematically prepare unsymmetrical 3‐formylfurans. Various 3‐formylfurans were prepared in good to excellent yields. In addition, the distinct fluorescence properties of 3‐formylfurans in solution and the solid state are disclosed

  通过设计合适的原料，已开发出了银（I）催化的环氧基开环/ 1,2-酰基迁移/环化级联反应，这使我们能够系统地制备不对称的3-甲酰基呋喃。制备了各种3-甲酰基呋喃，收率良好至优异。此外，还公开了溶液和固态中3-甲酰呋喃的不同荧光性质。
• Substituted anilinic piperidines as MCH selective antagonists
  申请人：Marzabadi R. Mohammad

  公开号：US20070043080A1

  公开（公告）日：2007-02-22

  This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.

  本发明涉及选择性拮抗黑色素浓集激素-1（MCH1）受体的化合物。本发明提供了一种药物组合物，包括本发明化合物的治疗有效量和药学上可接受的载体。本发明提供了一种由本发明化合物的治疗有效量和药学上可接受的载体组成的药物组合物。本发明还提供了一种制备药物组合物的方法，包括将本发明化合物的治疗有效量和药学上可接受的载体组合。
• Heterocyclic compound
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US08309580B2

  公开（公告）日：2012-11-13

  The present invention provides a heterocyclic compound represented by the following formula (I), which has a glucagon antagonistic action and is useful for the prophylaxis or treatment of diabetes and the like, a compound represented by wherein ring A is an optionally substituted benzene ring and the like; Y is a nitrogen atom and the like; X is —O— and the like; R4 is a hydrogen atom and the like; R5 and R6 are each independently a hydrogen atom and the like; R1 is an optionally substituted hydrocarbon group and the like; R2 is a hydrogen atom and the like; and R3 is —(CH2)3—COOH and the like, or a salt thereof.

  本发明提供了一种杂环化合物，其由以下式子（I）表示，具有葡萄糖升高素拮抗作用，用于预防或治疗糖尿病等疾病，其中化合物由以下表示： 其中环A是可选取代的苯环等；Y是氮原子等；X是—O—等；R4是氢原子等；R5和R6各自独立地是氢原子等；R1是可选取代的烃基等；R2是氢原子等；R3是—（CH2）3—COOH等，或其盐。
• HETEROCYCLIC COMPOUND AS GLUCAGON ANTAGONIST
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2210876B1

  公开（公告）日：2015-05-20
• SUBSTITUTED ANILINIC PIPERIDINES AS MCH SELECTIVE ANTAGONISTS
  申请人：Synaptic Pharmaceutical Corporation

  公开号：EP1411942A1

  公开（公告）日：2004-04-28